Edgewise Therapeutics, Inc. (EWTX)
NASDAQ
Market Cap
$1.63B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
47 of 809
Rank in Industry
39 of 445
Largest Insider Buys in Sector
EWTX Stock Price History Chart
EWTX Stock Performance
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Insider Activity of Edgewise Therapeutics, Inc.
Over the last 12 months, insiders at Edgewise Therapeutics, Inc. have bought $10.1M and sold $4.19M worth of Edgewise Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Edgewise Therapeutics, Inc. have bought $23.15M and sold $5.05M worth of stock each year.
Highest buying activity among insiders over the last 12 months: ORBIMED ADVISORS LLC () — $175M. Thompson Peter A. () — $25M. Fox Jonathan C (director) — $100,958.
The last purchase of 454,545 shares for transaction amount of $5M was made by Thompson Peter A. () on 2024‑01‑23.
List of Insider Buy and Sell Transactions, Edgewise Therapeutics, Inc.
| 2024-05-02 | Sale | Carruthers R Michael | Chief Financial Officer | 2,157 0.0023% | $18.91 | $40,789 | -9.39% | |
| 2024-05-02 | Sale | Donovan Joanne M. | CMO | 3,682 0.0039% | $18.91 | $69,627 | -9.39% | |
| 2024-05-02 | Sale | KOCH KEVIN | President and CEO | 3,152 0.0033% | $18.91 | $59,604 | -9.39% | |
| 2024-05-02 | Sale | Derakhshan Behrad | Chief Business Officer | 1,718 0.0018% | $18.91 | $32,487 | -9.39% | |
| 2024-05-02 | Sale | Russell Alan J | Chief Scientific Officer | 1,576 0.0017% | $18.91 | $29,802 | -9.39% | |
| 2024-05-02 | Sale | MOORE JOHN R | General Counsel | 1,956 0.0021% | $18.91 | $36,988 | -9.39% | |
| 2024-02-09 | Sale | Derakhshan Behrad | Chief Business Officer | 4,800 0.0065% | $20.04 | $96,209 | -11.56% | |
| 2024-02-09 | Sale | MOORE JOHN R | General Counsel | 8,029 0.0109% | $20.01 | $160,657 | -11.56% | |
| 2024-02-08 | Sale | Derakhshan Behrad | Chief Business Officer | 4,600 0.0063% | $20.01 | $92,049 | -12.92% | |
| 2024-02-08 | Sale | MOORE JOHN R | General Counsel | 3,813 0.0052% | $20.01 | $76,285 | -12.92% | |
| 2024-02-07 | Sale | Derakhshan Behrad | Chief Business Officer | 600 0.0008% | $20.00 | $12,000 | -13.47% | |
| 2024-02-07 | Sale | MOORE JOHN R | General Counsel | 17,993 0.0245% | $20.00 | $359,864 | -13.47% | |
| 2024-01-23 | Sale | Carruthers R Michael | Chief Financial Officer | 90,000 0.1441% | $15.78 | $1.42M | +11.23% | |
| 2024-01-23 | Thompson Peter A. | 454,545 0.5075% | $11.00 | $5M | +11.23% | |||
| 2024-01-23 | ORBIMED ADVISORS LLC | 454,545 0.5075% | $11.00 | $5M | +11.23% | |||
| 2023-12-27 | Sale | MOORE JOHN R | General Counsel | 8,497 0.0116% | $10.50 | $89,219 | +41.41% | |
| 2023-12-26 | Sale | Russell Alan J | Chief Scientific Officer | 172,585 0.2659% | $9.33 | $1.61M | +78.60% | |
| 2023-12-26 | Fox Jonathan C | director | 10,857 0.0167% | $9.30 | $100,958 | +78.60% | ||
| 2023-05-02 | Sale | Russell Alan J | Chief Scientific Officer | 1,602 0.0026% | $8.90 | $14,266 | -6.40% | |
| 2023-05-02 | Sale | Carruthers R Michael | Chief Financial Officer | 1,336 0.0021% | $8.90 | $11,897 | -6.40% |
Insider Historical Profitability
<0.0001%
| Thompson Peter A. | 14436497 16.9284% | $17.48 | 4 | 0 | <0.0001% | |
| ORBIMED ADVISORS LLC | 14436497 16.9284% | $17.48 | 4 | 0 | <0.0001% | |
| Carruthers R Michael | Chief Financial Officer | 35230 0.034% | $17.48 | 0 | 3 | |
| Fox Jonathan C | director | 10857 0.0127% | $17.48 | 1 | 0 | |
| Donovan Joanne M. | CMO | 19897 0.0117% | $17.48 | 0 | 2 | |
| KOCH KEVIN | President and CEO | 14478 0.0085% | $17.48 | 0 | 2 | |
| Derakhshan Behrad | Chief Business Officer | 13422 0.0082% | $17.48 | 0 | 5 | |
| Russell Alan J | Chief Scientific Officer | 7238 0.0042% | $17.48 | 0 | 28 | |
| MOORE JOHN R | General Counsel | 3252 0% | $17.48 | 0 | 15 | |
| OrbiMed Genesis GP LLC | 13497456 15.8273% | $17.48 | 1 | 0 | +30.03% | |
| Novo Holdings A/S | 10 percent owner | 6071703 7.1197% | $17.48 | 2 | 0 | <0.0001% |
| Flynn James E | 10 percent owner | 3933137 4.612% | $17.48 | 1 | 0 | <0.0001% |
| ROOT JONATHAN D | director | 15625 0.0183% | $17.48 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| OrbiMed | $274M | 16.08 | 15.02M | +3.12% | +$8.29M | 5.6 | |
| RA Capital Management, L.P. | $162.5M | 9.54 | 8.91M | New | +$162.5M | 0.16 | |
| Fidelity Investments | $116.11M | 6.82 | 6.37M | -1.95% | -$2.31M | 0.01 | |
| Baker Bros Advisors LP | $106.52M | 6.25 | 5.84M | +87.61% | +$49.75M | 1.34 | |
| BlackRock | $94.25M | 5.53 | 5.17M | +56.24% | +$33.92M | <0.01 | |
| The Vanguard Group | $73.28M | 4.3 | 4.02M | +89.02% | +$34.51M | <0.01 | |
| Viking Global Investors | $60.91M | 3.58 | 3.34M | -45.79% | -$51.44M | 0.02 | |
| Frazier Life Sciences Management L P | $60.26M | 3.54 | 3.3M | +23.86% | +$11.61M | 3.09 | |
| Cormorant Asset Management Lp | $54.84M | 3.22 | 3.01M | +17.81% | +$8.29M | 2.6 | |
| Deerfield Management | $52.43M | 3.08 | 2.87M | -26.91% | -$19.31M | 1.01 | |
| Citadel Advisors LLC | $49.6M | 2.91 | 2.72M | +5.16% | +$2.43M | 0.03 | |
| Paradigm BioCapital Advisors LP | $44.62M | 2.62 | 2.45M | New | +$44.62M | 1.62 | |
| Perceptive Advisors | $42.31M | 2.48 | 2.32M | +317.54% | +$32.18M | 0.03 | |
| Tcg Crossover Management Llc | $41.45M | 2.43 | 2.27M | New | +$41.45M | 0.07 | |
| Vr Adviser Llc | $33.16M | 1.95 | 1.82M | New | +$33.16M | 1.61 | |
| Janus Henderson | $32.9M | 1.93 | 1.81M | +48.58% | +$10.76M | 0.02 | |
| Goldman Sachs | $31.88M | 1.87 | 1.75M | +98.19% | +$15.79M | 0.01 | |
| New Leaf Venture Partners | $28.34M | 1.66 | 1.55M | 0% | +$0 | 24.84 | |
| Geode Capital Management | $24.99M | 1.47 | 1.37M | +44.65% | +$7.71M | <0.01 | |
| Driehaus Capital Management LLC | $23.13M | 1.36 | 1.27M | +220.91% | +$15.92M | 0.23 | |
| Ecor1 Capital Llc | $22.81M | 1.34 | 1.25M | -64.2% | -$40.91M | 0.58 | |
| State Street | $22.1M | 1.3 | 1.21M | +35.71% | +$5.81M | <0.01 | |
| Artal Group S A | $14.81M | 0.87 | 811,718 | New | +$14.81M | 0.08 | |
| Opaleye Management Inc | $12.13M | 0.71 | 665,000 | -4.86% | -$620,160.00 | 1.92 | |
| Parkman Healthcare Partners Llc | $11.92M | 0.7 | 653,653 | +0.31% | +$36,990.72 | 1.47 | |
| Granahan Investment Management | $11.09M | 0.65 | 608,012 | -43.44% | -$8.52M | 0.39 | |
| American Century Investments | $10.2M | 0.6 | 559,334 | -27.4% | -$3.85M | 0.01 | |
| Millennium Management LLC | $9.71M | 0.57 | 532,255 | +305.2% | +$7.31M | 0.01 | |
| Northern Trust | $9.11M | 0.54 | 499,520 | +37.52% | +$2.49M | <0.01 | |
| Charles Schwab | $9.07M | 0.53 | 497,162 | +50.17% | +$3.03M | <0.01 | |
| D. E. Shaw & Co. | $8.64M | 0.51 | 473,680 | +1,382.57% | +$8.06M | 0.01 | |
| Wellington Management Company | $8.63M | 0.51 | 472,903 | +38.72% | +$2.41M | <0.01 | |
| Bioimpact Capital Llc | $8.05M | 0.47 | 441,259 | New | +$8.05M | 1.3 | |
| Woodline Partners LP | $7.39M | 0.43 | 405,132 | +0.23% | +$16,780.80 | 0.07 | |
| Two Sigma | $7.16M | 0.42 | 392,735 | +131.65% | +$4.07M | 0.01 | |
| Morgan Stanley | $6.83M | 0.4 | 374,718 | +66.41% | +$2.73M | <0.01 | |
| Nuveen | $6.17M | 0.36 | 338,004 | +120.5% | +$3.37M | <0.01 | |
| Candriam S C A | $6M | 0.35 | 329,000 | +6.82% | +$383,040.00 | 0.04 | |
| DAFNA Capital Management, LLC | $5.59M | 0.33 | 306,197 | -31.86% | -$2.61M | 1.3 | |
| Dimensional Fund Advisors | $5.46M | 0.32 | 299,288 | +14.13% | +$675,791.98 | <0.01 | |
| Kennedy Capital Management Inc | $5.35M | 0.31 | 293,265 | -14.47% | -$904,685.83 | 0.11 | |
| Schonfeld Group | $5.19M | 0.31 | 284,600 | -10.81% | -$629,280.00 | 0.04 | |
| BNY Mellon | $3.87M | 0.23 | 212,265 | +45.22% | +$1.21M | <0.01 | |
| Voloridge Investment Management, LLC | $3.21M | 0.19 | 175,901 | New | +$3.21M | 0.01 | |
| Trexquant Investment LP | $2.3M | 0.14 | 126,332 | +127.25% | +$1.29M | 0.03 | |
| Cubist Systematic Strategies | $1.88M | 0.11 | 103,208 | +5,869.23% | +$1.85M | 0.02 | |
| Two Sigma Advisers LP | $1.69M | 0.1 | 92,400 | +125.92% | +$939,360.00 | <0.01 | |
| Barclays | $1.59M | 0.09 | 87,244 | -88.8% | -$12.61M | <0.01 | |
| RhumbLine Advisers | $1.54M | 0.09 | 84,228 | +30.93% | +$362,881.56 | <0.01 | |
| DekaBank | $1.44M | 0.09 | 80,000 | 0% | +$0 | <0.01 |